|
|
|
Targeted approaches to cancer treatment are showing increasing signs of success as alternatives to traditional chemotherapy. In the March issue of Nature Medicine, Karen Miller and colleagues use one such drug, called VX-680, to suppress tumor growth.
VX-680 inhibits the enzymatic activity of Aurora kinases, proteins that have an important role in cell division. Because cancer cells divide rapidly, blocking Aurora kinases selectively targets those cells. The authors show that, in a mouse model of cancer, VX-680 inhibits the proliferation of cancer cells, resulting in slower tumor growth. If further studies confirm the results, VX-680 might be used to specifically target tumor cells and minimize the side effects and toxicity seen with other cancer therapies, the authors suggest. Author contact: Karen M. Miller
Vertex Pharmaceuticals (Europe) Ltd.
Abingdon, UK
Tel: +44 1235 438810
E-mail: karen_miller@vrtx.com Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|